What's Happening?
Intellia Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) accepting its Biologics License Application (BLA) for lonvo-z, a therapy designed to edit DNA inside the body for Hereditary Angioedema (HAE).
The FDA has granted lonvo-z Priority Review, with a target action date of March 10, 2027. This marks a potential global first for an in vivo gene-editing therapy. Phase 3 results from the HAELO trial, involving 80 patients, demonstrated that lonvo-z significantly reduced mean monthly HAE attacks by 87% compared to placebo over weeks 5 to 28. Furthermore, 62% of treated patients were attack-free and therapy-free over six months, versus 11% in the placebo group. The therapy was generally well-tolerated, with no serious adverse events reported in the lonvo-z arm, and treatment-emergent events were mild or moderate.
Why It's Important?
The FDA's Priority Review for lonvo-z underscores the potential for in vivo gene editing to revolutionize treatment for genetic diseases. If approved, lonvo-z would be the first in vivo CRISPR-based therapy, setting a precedent for future gene-editing treatments that directly modify DNA within a patient's body. This development is crucial for patients with Hereditary Angioedema, a debilitating condition, as it offers a potentially long-lasting solution compared to existing therapies that require repeated administration. The success of lonvo-z could accelerate investment and research in other in vivo gene-editing applications, particularly for liver-directed therapies, given the liver's accessibility for lipid nanoparticle delivery. This advancement also highlights the growing confidence of regulatory bodies in the safety and efficacy of CRISPR technology, paving the way for broader adoption and commercialization of gene-editing medicines across various therapeutic areas.
What's Next?
The primary next step is the FDA's decision on lonvo-z's BLA by the target action date of March 10, 2027. Intellia Therapeutics anticipates a U.S. launch in the first half of 2027, assuming approval. Beyond lonvo-z, the field of in vivo gene editing is rapidly advancing, with several other programs reporting human data. Eli Lilly plans to initiate Phase 2 trials for VERVE-102, a base editor for high cholesterol, by the end of 2026. CRISPR Therapeutics is expected to present Phase 1b data for CTX310, targeting ANGPTL3 for dyslipidemias, at the American Heart Association Scientific Sessions on November 9, 2026. Beam Therapeutics is dosing a pivotal cohort for BEAM-302 for alpha-1 antitrypsin deficiency, with an aim for accelerated FDA approval based on biomarker data. Prime Medicine has dosed its first patient with PM577a for Wilson disease, with initial data expected in 2027. These ongoing developments indicate a busy period of clinical data releases and regulatory decisions in the coming years.
Beyond the Headlines
The potential approval of lonvo-z extends beyond HAE, signaling a broader shift in therapeutic paradigms. It validates the concept of a single-infusion, durable genetic treatment, which could significantly reduce the burden of chronic disease management for patients and healthcare systems. However, critical questions remain regarding long-term durability beyond two years, clinical outcomes (especially for cardiovascular programs that currently measure blood markers rather than hard endpoints like heart attacks), and the reach of gene editing beyond the liver. The pricing and reimbursement models for such one-time, potentially curative therapies will also be a significant challenge for health systems. Furthermore, the tragic death of a patient in Intellia's MAGNITUDE trial for nex-z, despite the clinical hold being lifted, underscores the inherent risks and the need for continuous vigilance in patient safety and monitoring. The identification of a specific HLA allele linked to higher liver enzyme elevations in that trial suggests a future where genetic screening could mitigate some of these risks, adding another layer of precision to gene-editing therapies.
